SlideShare a Scribd company logo
Sandro C. Esteves
ANDROFERT & University of Campinas (UNICAMP),
Campinas, BRAZIL
Aarhus University, DENMARK
Oocyte number and
success in ART –
The “ART Calculator”
Esteves, 2
Sandro Esteves, MD., PhD.
• Medical and Scientific Director, ANDROFERT, Campinas, BRAZIL
• Collaborating Professor, Department of Surgery, University of Campinas
(UNICAMP), BRAZIL
• Research Collaborator, American Center for Reproductive Medicine, Cleveland
Clinic, USA
• Research Collaborator, Genetic Unit, Universidad Autónoma de Madrid, SPAIN
• Honorary Professor of Reproductive Endocrinology, Faculty of Health, Aarhus
University, DENMARK
Declare receipt of honoraria for lectures from Merck, Besins, Gedeon
Richter, and Lilly
Affiliation & Disclosure
1. Importance of oocyte number and female age in
ART success
2. Estimation of individualized oocyte number for
modelling patient-oriented strategies as a
means to increase ART efficiency
Lecture Outline
Esteves, 3
Modified from Smith et al. JAMA 2015
156,947 UK women
(257,398 IVF cycles;
cumulative LBR using
fresh and frozen ET)
With increased women’s age in ART programs,
we should maximize reproductive outcomes and shorten TTLB
Esteves, 4
Quality Dimensions
1. Effectiveness (Technical aspects to deliver the best outcome)
2. Safety (risks, adverse effects, lab quality, etc.)
3. Patient centeredness (patient values and preferences)
Success in ART
The bottom line
• Evaluate properly
• Give a fair estimate of outcome
• Develop a time-limited treatment plan
Dancet et al. Hum Reprod 2011; Mainz. Int J Qual Health Care 2003
Esteves, 5
AMH and AFC predict ovarian response but not LBR
AMH~AFC>FSH>Age
Predictors of Poor
Response
Predictors of Excessive
Response
Accuracy for Non-Pregnancy
Prediction ~ 50-55%
Modified from Broer et al. Fertil Steril 2009 Modified from Broer et al. Fertil Steril 2009Modified from Broer et al. Hum Reprod Update 2011
Accuracy ~0.82 Accuracy ~0.78
Esteves, 6
Female age and number of oocytes can predict LBR
Modified from McLernon et al. BMJ 2016
Modified from Sunkara et al. Hum Reprod 2011
Modified from De Geyter et al. Swiss Med Wkly 2015
Esteves, 7
Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number
POSEIDON GROUP
Poseidon Group. Fertil Steril 2016
Esteves, 8
Low prognosis groups
Young Older
Adequate
ovarian
reserve
Poor
ovarian
reserve
Courtesy of Chloe Xilinas, EXCEMED
Poseidon Group. Fertil Steril 2016; Humaidan et al. F1000Research 2016
2
2
Esteves, 9
Prevalence of low prognosis patients according
to POSEIDON criteria
5% 30%
10% 55%
47%
Poseidon
1-4
53%
Non Poseidon
N=432 – YEAR 2017
Source: ANDROFERT
Esteves, 10
Modified from Drakopoulos et al. Hum Reprod 2016
Low Prognosis Owing to Decreased Number of Oocytes
and thus lower CLBR
Poseidon Patients
Age-adjusted CLBR strongly influenced by oocyte number
* Age adjusted (OR: 0.9; 95% Cl: 0.9-1.01)
21.7%
39.7%
50.5%
61.5%p=0.002
p=0.02
p=0.01
Esteves, 11
Group 1
Young & Suboptimal/Low
Oocyte Number
Group 2
Old & Suboptimal/Low
Oocyte Number
Group 3
Young & Expected Low
Oocyte Number
Group 4
Old & Expected Low
Oocyte Number
High
embryo
aneuploidy
risk
Low
embryo
aneuploidy
risk
Few embryos generated
Reduced Cumulative Live Birth Rate
Poseidon
Patients
Esteves, 12
Esteves et al., ESHRE 2018; P-394
The older the women the lower the probability of euploid
embryos, thus increasing the risk of NO transferable embryos
Euploidy probability vs Female age
Cycles with no transferable embryos
Courtesy of Chloe Xilinas, EXCEMED
Courtesy of Ubaldi & Rienzi. Genera
Jan 2012 – Dec 2013
Esteves, 13
Estimation of Age-dependent Decrease in Blastocyst
Euploidy by Next Generation Sequencing - Development of
a Novel Prediction Model
Quadratic model on age significant (Prob>ChiSquare=0.028);
derived model was log[p(t)/(1−p(t))]=7.575-0.21⋅age-0.011⋅(age-38.41)2,
where p(t) is the probability of a blastocyst being euploid for age (t) in years.
Term Estimate Std Error Wald
ChiSquare
Prob >
ChiSquare
Lower
95%
Upper
95%
Intercept
7.5746663 1.028021 54.290324 <.0001* 5.5597808 9.5895518
age
-0.212288 0.026273 65.284544 <.0001* -0.263783 -0.160793
(age-
38.4082)*(age-
38.4082)
-0.01059 0.004834 4.7979866 0.0285* -0.020066 -0.001114
Esteves, Carvalho, Martinhago, Melo, Bento, Humaidan & Alviggi. Panminerva Medica 2018 ahead of print
Esteves, 14
Euploidy probability vs Female age
Measure
Training Validation
Number of rows
1,036 260
Sum of
Frequencies 1,036 260
-LogLikelihood
588.50165 139.70103
Number of
Parameters 3 3
BIC
1197.6537 295.89356
AICc
1183.028 285.50206
Generalized
RSquare 0.1162863 0.1893375
Validation by randomly splitting 80% of the data
for training and 20% for testing
Esteves, Carvalho, Martinhago, Melo, Bento, Humaidan & Alviggi. Panminerva Medica 2018 ahead of print
Esteves, 15
Esteves et al., ESHRE 2018; O-007
Progressive decline* in blastocyst euploidy
probability as a function of female age
Analysis of 1,220 trophectoderm biopsies from 436 patients undergoing
ICSI and PGT-A with NGS
1.2 1.9 2.6 3.4 4.4
5.5
6.7
8.2
9.8
11.6
13.6
15.7
17.9
20.2
22.4
24.5
26.6
Geometric mean of the yearly variation: 13.6%
*The % decrease in blastocyst euploidy
probability from year (t) to year (t+1) was
defined as the ratio p(t+1)/p(t) x 100
Esteves, 16
Number of oocytes needed to maximize live births should be
individualized
Female age is a critical factor to
be taken into account
Patient-oriented strategies can
be used to achieve the
individualized oocyte number
Esteves, 17
Introduced an Intermediate Marker of Success in ART:
the Ability to Retrieve the Number of Oocytes Needed to Obtain
at Least One Euploid Blastocyst for Transfer in Each Patient
Poseidon Group. Fertil Steril 2016; Humaidan et al. F1000Research 2016
What is new in POSEIDON?
Introduced the Concept of ‘Low Prognosis’ in ART
Combined Oocyte Quality and Quantity for Identification
and Stratification of the ’Low Prognosis’ Patient
Included ’Hypo-responders’ as a Distinct Category
of ’Low Prognosis’ Patients
Introduced an Intermediate Marker of Success in ART:
the Ability to Retrieve the Number of Oocytes Needed to Obtain
at Least One Euploid Blastocyst for Transfer in Each Patient
Esteves, 18
Courtesy of Ubaldi & Rienzi (GENERA; Jan 2012-Dez 2013)
Source: ANDROFERT; Jan 2015-Sept 2016 (PGT-A by NGS)
Live birth (%)
Availability of euploid embryos maximizes IVF efficiency by
offsetting the negative effect of age on implantation and
pregnancy
Esteves, 19
http://www.members.groupposeidon.com/Calculator
Estimation can be done by means of a mathematical function
taking into account relevant predictive factors
Input variables
• Maturation rate
• 2PN Fertilization rate
• Cleavage or Blastulation rate
• Euploidy rate per age group
Adjusted according to maternal
and paternal age, sperm source,
sperm and oocyte status,
and type of embryo transfer
(fresh; FET)
Output variable
Y (N oocytes)
Function
Y = f(X)
Esteves, 20
There are two ways to do that…
the HARD WAY the EASY WAYand
Esteves, 21
The easy way
http://www.members.groupposeidon.com/Calculator
Esteves, 22
age p N (P=0.8) N (P=0.9)
28 0.6748 2 3
29 0.6665 2 3
30 0.6538 2 3
31 0.6365 2 3
32 0.6144 2 3
33 0.5873 2 3
34 0.5549 2 3
35 0.5174 3 4
36 0.4750 3 4
37 0.4283 3 5
38 0.3784 4 5
39 0.3268 5 6
40 0.2753 5 8
41 0.2259 7 9
42 0.1803 9 12
43 0.1399 11 16
44 0.1056 15 21
45 0.0775 20 29
Minimum number (N) of blastocysts required to achieve at least one euploid blastocyst for
transfer, with probabilities (P) of 0.8 and 0.9, where “p” is the model-estimated probability
of a blastocyst being euploid for female age in years
Esteves, Carvalho, Martinhago, Melo, Bento, Humaidan & Alviggi. Panminerva Medica 2018 ahead of print
Esteves, 23
Model
Estimates (No.
embryos by
female age)
Esteves, Carvalho, Martinhago, Melo, Bento, Humaidan & Alviggi. Panminerva Medica 2018 ahead of print
Esteves, 24
http://www.members.groupposeidon.com/Calculator
Esteves, 25
The most optimal treatment strategy is planned with the
mindset to achieve the POSEIDON marker of success
GnRH analogue regimen
Gonadotropin dose and drug type
Trigger strategy
Adjuvant therapy
Combined strategies (AccuVit; Duostim, etc.)
Personalized use of laboratory technology
Personalized luteal phase support
Esteves, 26
Agonist or Antagonist +
rFSH alone or rFSH + LH
Agonist or Antagonist + rFSH + LH
GnRH Antagonist + Low dose rFSH (100-175 IU) GnRH Antagonist + rFSH + LH
Poseidon
G1 Poseidon
G2 Poseidon
G3 Poseidon
G4
Non
Poseidon
patients
Andersen et al. (eds.) Research Topic Frontiers in Endocrinology. In preparation
It is important to use the right FSH starting dose and adapt it during
the cycles to optimize the number of oocytes retrieved and at the
same time minimize risks such as OHSS and cycle cancellation
Esteves, 27
Esteves, Yarali, Ubaildi et al. Validation of ART Calculator Consortium;
Unpublished data
No detrimental effects on embryo ploidy in patients
who retrieve more oocytes
Response Number Euploid Blastocysts
Distribution Binomial
Estimation Method Logistic Regression
Validation Method Validation Column
Probability Model Link Logit
Generalized Regression for number
Euploid Blastocysts Model Launch
Lasso [x] Adaptive
Term Estimate Std Error
Wald
ChiSquare
Prob >
ChiSquare
Lower
95%
Upper
95%
Intercept 6.2769104 0.6256681 100.64771 <0.0001* 5.0506235 7.5031972
Age Female -0.182507 0.152275 143.64894 <0.0001* -0.212352 -0.152662
Number
Blastocysts
0.0302516 0.0189943 2.536584 0.1112 -0.006977 0.0674797
Parameter Estimates for Original Predictors
3,108 Trophectoderm Biopsies
1,109 patients
Euploidy probability vs. number
of blastocysts by age group
Esteves, 28
Higher ovarian response than that achieved with mild/natural
ovarian stimulation does not increase risk of embryo aneuploidy
Term Estimate Std Error
Wald
ChiSquare
Prob >
ChiSquare
Lower
95%
Upper
95%
Intercept 3.8117137 1.5331832 6.1809102 0.0129* 0.8067298 6.8166876
Age Female -0.22129 0.019748 125.56789 <0.001* -0.259996 -0.182585
typeOSGrou
ped[Convent
ional-Other]
0.065727 0.33909 0.0375714 0.8463 -0.598877 0.7303311
Response Number Euploid Blastocysts
Distribution Binomial
Estimation Method Adaptive Lasso
Validation Method Validation Column
Probability Model Link Logit
Adaptive Lasso with Validation Column Model Summary
Parameter Estimates for Original Predictors
1,632 Trophectoderm Biopsies by NGS
631 patients
Euploidy probability vs Female Age, by OS Type
Esteves, Yarali, Ubaildi, et al. Validation of ART Calculator Consortium;
Unpublished data
Esteves, 29
Administration of an inappropriately low gonadotrophin dose
may lead to the growth of a low number of follicles resulting
in an ‘iatrogenic’ poor or suboptimal response
• Type of Gonadotropin
• FSH Dose
• Add LH
Courtesy of Chloe Xilinas, EXCEMED
Esteves, 30
Unpublished data; Source: ANDROFERT
Current Practice – Flexibility of iCOS
Rec-hFSH
Starting Dose Distribution (%)
% cycles with
Dose Adaptation after Sd5
53.4%
Esteves, 31
Current Practice – Flexibility of iCOS
% cycles
by Trigger Method
% cycles
with LH Activity Supplementation
12%
Dual trigger
43%
GnRH analog
45%
hCG
57%
Rec-LHc
43%
No-LH
Unpublished data; Source: ANDROFERT
Esteves, 32
Target number of oocytes difficult to achieve by a single OS cycle
http://www.members.groupposeidon.com/Calculator
Courtesy of Chloe Xilimas, EXCEMED
Esteves, 33
Haahr, Esteves & Humaidan. Reprod Biol Endocrinol 2018
Management of Poseidon poor prognosis patients
<AFC <5 and/or AMH <1.2 ng/ml
Group 3, young (AGE <35) Group 4, old (AGE ³35)
Poor reserve - good quality Poor reserve - poor quality
Reason for poor response:
• Poor ovarian reserve
• Asynchronous development
(Genetic polymorphism of FSH-R; LH-R; V-LH-β)
iCOS Treatment:
• Long GnRHa protocol
• GnRH antagonist (E2, OCP)
• DuoStim ?
• Stimulation with 300 IU/d rFSH
• Androgens ?
Embryo Transfer strategy:
• Fresh transfer
• Oocyte/embryo accumulation and FET
Measure of success:
In average, a total of 4-5 oocytes are needed
to obtain one euploid embryo
Reason for poor response:
• Poor ovarian reserve
• Asynchronous development
• High Aneuploidy rate
(Genetic polymorphism of FSH-R; LH-R; V-LH-β)
iCOS Treatment:
• Long GnRHa protocol
• GnRH antagonist (E2, OCP)
• DuoStim
• Stimulation with 300 IU/d rFSH
• Androgens ?
Embryo Transfer strategy:
• Fresh transfer
• Oocyte/embryo accumulation, PGS?
and FET (Oocyte donation)
Measure of success:
In average, a total of 12 oocytes are needed
to obtain one euploid embryo
Esteves, 34
Modified from Ubaldi et al. Fertil Steril 2016
Dual stimulation
Courtesy of Chloe Xilinas, EXCEMED
rFSH or rFSH+LH rFSH or rFSH+LH
Esteves, 35
Male age!
Does it matter?
Ramajit Raghav,
94 yo.
Indian farmer claims to be the oldest dad in the world, and says he wants more…
Female age is key
Review Criteria
An extensive search of studies examining the influence of paternal age on
ART outcomes was performed using PubMed and MEDLINE. The start date
for the search was January 2008, and the end date was March 2018.
The overall strategy for study identification and data extraction was based on
the following keywords: “paternal age”, “male age factor”, “masculine age
factor”, “male ageing”, “paternal ageing”, “reproductive techniques”,
“assisted”, “ICSI”, “in vitro fertilization” “sperm injections”, “intracytoplasmic”,
“IVF”, with the filters “humans” and “English language.” Data that were solely
published in conference or meeting proceedings, websites or books were not
included. Citations dated outside the search dates were only included if
provided conceptual content.
ESTEVES, 39CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 39
Study Country Number Main findings Age cutoff
Frattarelli
2008
USA 1023
Decline in semen volume and total motile sperm
number
45
Bellver 2008 Spain 2698
Negative association between age and semen volume,
sperm concentration, and total progressive motility
NR
Girsh, 2008 Israel 484 Male age higher in non-pregnant group; Conventional
semen parameters lower in men aged >50
50
Ferreira, 2010 Brazil 1024 No effect of age on sperm concentration and motility NR
Duran 2010 USA 408
Semen volume, sperm motility and fertilization rates
inversely correlated with age
NR
Nijs, 2011 Belgium 278
No correlation between male age and sperm
concentration, progressive motility, and DFI
NR
Varshini, 2011 India 504 DFI increased in men older than 40 years 40
Stone, 2013 USA 5081
Total sperm numbers fall by ~2% per year, morphology
by ~0.8% per year, and total sperm motility by ~2%
35
Alshahrani,
2014
USA 472
No significant differences in conventional semen
parameters. Higher DFI in men >40y
40
Beguería, 2014 Spain 4887
Semen volume and %motile sperm decreased with a
mean reduction of 0.22 ml and 1.2% every 5 years
NR
Kaarouch,
2018
Morocco 204
No effect on conventional semen parameters; Higher
DFI and sperm aneuploidy in older men
40
Paternal age X semen parameters
Bertoncelli Tanaka et al. Panminerva Med. 2018 Jul 18. [Epub ahead of print]
Author	 Country
Number	
(cycles)
Method
Egg	donation	
model
Fertilization Embryo	
development
Pregnancy
Miscarriage/	
stillbirth
Live	birth	 Age cutoff
Gu,	2012 China 103 IVF Yes No	effect NR No	effect No	effect No	effect NA
Robertshaw,	2014 USA 237 IVF Yes NR NR NR
Increase	in	pregnancy	loss	
with	aging
26%	lower	odds	of	LB	with	each	5-
year	increase	in	age
NR
Wu,	2015 China 9991 IVF No No	effect No	effect
Lower	in	men	>36y	than	
<32	y	(women	30-34y)	
No	effect No	effect 36
Girsh,	2008 Israel 484 ICSI Yes No	effect Decreased	 Decreased	 NR NR 40-50
Ferreira,	2010 Brazil 1024 ICSI No NR No	effect
Decreased	by	5%	for	
each	year	of	age	in	
oligozoospermia	
No	effect NR NR
Tsai,	2013 Taiwan 184 ICSI No No	effect No	effect No	effect No	effect No	effect NA
Ramasamy,	2014 USA 1046 ICSI No NR NR Decreased	 NR NR 50
Beguería,	2014 Spain 4887 ICSI Yes No	effect No	effect No	effect No	effect No	effect NA
Frattarelli,	2008 USA 1023 IVF	and	ICSI No No	effect
Reduced	blastocyst	
formation	
No	effect Increased	miscarriage	 Decreased	 55
Bellver,	2008 Spain 2698 IVF	and	ICSI Yes No	effect No	effect No	effect No	effect NR NA
Campos,	2008 Spain 915 IVF	and	ICSI Yes No	effect No	effect Decreased	 No	effect NR 39
Luna,	2009 USA 672 IVF	and	ICSI Yes Decreased	
Reduced	blastocyst	
formation	
No	effect No	effect	 NR 40*	and	60‡
Duran,	2010 USA 519 IVF	and	ICSI Yes Decreased	 No	effect No	effect No	effect No	effect 50
Ghuman,	2016 UK 7104 IVF	and	ICSI No NR NR No	effect No	effect NR NA
Meijerink,	2016 Netherlands 7051 IVF	and	ICSI No No	effect No	effect No	effect NR NR NA
McPherson,	2017 Australia 2215 IVF	and	ICSI No No	effect NR See	LBR NR
10%	lower	pregnancy	and	LBR	in	
women	aged	35	years	with	
partners >40	years	than	women	
aged	35	years	with	partners	<30	
years
40
Tiegs,	2017 USA 573 IVF	and	ICSI Yes Decreased	 No	effect No	effect No	effect No	effect 45
Chapuis,	2017 France 2491 IVF	and	ICSI No No	effect
Reduced	blastocyst	
formation	
Decreased	in	ICSI	but	
not	with	IVF	
No	effect		 — 50
Park, 2017 Korea 452 ICSI No No	effect No	effect Decreased	 NR Decreased	 46
Kaarouch, 2018 Morocco 83 IVF No Decreased	 Decreased	 Decreased	 Increased NR 40
Bertoncelli Tanaka	et	al.	Panminerva Med.	2018	Jul	18.	[Epub ahead	of	print]	
Paternal age X IVF outcomes
ESTEVES,	41
ESTEVES, 42
ESTEVES, 42
CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA
ESTEVES, 43
Esteves, Yarali, Ubaldi et al; ART Calculator Validation Consortium, Unpublished
data
Paternal age and
blastocyst genetic status
1070
patients
TB + NGS
CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 43
Age
CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES,	44
Cho, Esteves, Agarwal. Curr Opin Obstet Gynecol 2016
Finding the link
Aitken, Reproduction 2014; 147:S1-S11
Mechanism of oxidative-induced sperm DNA damage
OGG1:	8-oxi	guanine	glicosylase
CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES,	45
Activity	of	OGG1	decreases	with	advanced	paternal	
age,	thus	resulting	in	8-oxi	guanine	accumulation
Sperm chromatin repair mechanisms
CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES,	46
Champroux et	al.	Basic	and	Clin Androl 2016;	26:17
OGG1	is	deficient	
in	oocytes;	
8OHdG	carried	to	
embryos	by	
fertilizing	sperm
8OHdG	highly	
mutagenic	(G-T	
transversion)
proband schizophrenic Kong	et	al.	Nature	2012;	488:471
proband a parent of an autistic case
♦ proband autistic
An exponential model estimates
paternal mutations doubling every
16.5 years
Paternal age and germline mutations
CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES,	47
Guanine	
particularly	
vulnerable
Oxidative stress causes harm to DNA
No.oxidizedregions
Chromosome size
Imunoprecipitação 8OHdG
chrX
chrY
chr15
CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES,	48
Impact of paternal age on
neurodevelopmental status of naturally
conceived offspring
Autism
Bipolar	disease/schizophrenia	
Marfan syndrome
Paternal age (yrs)
Oddsratio
Bipolar disease
Frans	et	al.	Arch	Gen	
Psychiatry	2008;	
65:1034
Paternal age (yrs)
Oddsratio
Autism
Reichenberg	et	al.	Arch	
Gen	Psychiatry	2006;	
63:1026
CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA
CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES,	49
POSEIDON–based
Stratification
FSH Starting Dose
Gonadotropin Dose
Adaptation
Flexible OS
(eg. LH, Duostim,
trigger)
Maximize oocyte yield
to achieve estimated
N oocytes for at least
1 euploid embryo
(ART Calculator)
Reduced
Time to Live Birth
Conclusions
Esteves, 50
51
iART
Esteves, 51
www.groupposeidon.com
http://www.members.groupposeidon.com/Calculator
Esteves, 52

More Related Content

What's hot

what is new in controlled ovarian stimulation?
what is new in controlled ovarian stimulation?what is new in controlled ovarian stimulation?
what is new in controlled ovarian stimulation?
Aboubakr Elnashar
 
Optimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cyclesOptimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cycles
nermine amin
 
Controlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIControlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUI
Bharati Dhorepatil
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
Aboubakr Elnashar
 
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
DR SHASHWAT JANI
 
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi BanerjeeOvulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Kaberi Banerjee
 
Progesterone rise and IVF success
Progesterone rise and IVF successProgesterone rise and IVF success
Progesterone rise and IVF success
Sandro Esteves
 
Difficult Cases in IUI
Difficult Cases in IUIDifficult Cases in IUI
Difficult Cases in IUI
Sujoy Dasgupta
 
POOR RESPONDERS
POOR RESPONDERS POOR RESPONDERS
POOR RESPONDERS
Meenakshi Vempalli
 
Optimize oocyte yield to maximize live birth in ART
Optimize oocyte yield to maximize live birth in ARTOptimize oocyte yield to maximize live birth in ART
Optimize oocyte yield to maximize live birth in ART
Sandro Esteves
 
Ovarian stimulation
Ovarian stimulationOvarian stimulation
Ovarian stimulation
Aboubakr Elnashar
 
Adjuvants in por (1)
Adjuvants in por (1)Adjuvants in por (1)
Adjuvants in por (1)
rupalibassi
 
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVFCURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
Aboubakr Elnashar
 
Fertility Challenges In Women With Biologically challenged Ovaries poor respo...
Fertility Challenges In Women With Biologically challenged Ovariespoor respo...Fertility Challenges In Women With Biologically challenged Ovariespoor respo...
Fertility Challenges In Women With Biologically challenged Ovaries poor respo...
Rupal Shah
 
Ivf in pcos
Ivf in pcosIvf in pcos
Ivf in pcos
Aboubakr Elnashar
 
Iui - newer concepts
Iui  - newer conceptsIui  - newer concepts
Iui - newer concepts
Dr Sachin Dalal
 
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal  Dr. Jyoti Bh...Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal  Dr. Jyoti Bh...
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...
Lifecare Centre
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
Bharati Dhorepatil
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation induction
sunitafeme
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
Aboubakr Elnashar
 

What's hot (20)

what is new in controlled ovarian stimulation?
what is new in controlled ovarian stimulation?what is new in controlled ovarian stimulation?
what is new in controlled ovarian stimulation?
 
Optimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cyclesOptimal endometrial preparation for frozen embryo transfer cycles
Optimal endometrial preparation for frozen embryo transfer cycles
 
Controlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUIControlled Ovarian Hyperstimulation With IUI
Controlled Ovarian Hyperstimulation With IUI
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
 
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
Panel IUI by DR SHASHWAT JANI ( Optimizing Success in Intrauterine Inseminati...
 
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi BanerjeeOvulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
Ovulation Induction in Different Case Scenario- Dr. Kaberi Banerjee
 
Progesterone rise and IVF success
Progesterone rise and IVF successProgesterone rise and IVF success
Progesterone rise and IVF success
 
Difficult Cases in IUI
Difficult Cases in IUIDifficult Cases in IUI
Difficult Cases in IUI
 
POOR RESPONDERS
POOR RESPONDERS POOR RESPONDERS
POOR RESPONDERS
 
Optimize oocyte yield to maximize live birth in ART
Optimize oocyte yield to maximize live birth in ARTOptimize oocyte yield to maximize live birth in ART
Optimize oocyte yield to maximize live birth in ART
 
Ovarian stimulation
Ovarian stimulationOvarian stimulation
Ovarian stimulation
 
Adjuvants in por (1)
Adjuvants in por (1)Adjuvants in por (1)
Adjuvants in por (1)
 
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVFCURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
 
Fertility Challenges In Women With Biologically challenged Ovaries poor respo...
Fertility Challenges In Women With Biologically challenged Ovariespoor respo...Fertility Challenges In Women With Biologically challenged Ovariespoor respo...
Fertility Challenges In Women With Biologically challenged Ovaries poor respo...
 
Ivf in pcos
Ivf in pcosIvf in pcos
Ivf in pcos
 
Iui - newer concepts
Iui  - newer conceptsIui  - newer concepts
Iui - newer concepts
 
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal  Dr. Jyoti Bh...Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal  Dr. Jyoti Bh...
Ovulation Induction in I.U.I. Dr. Sharda Jain Dr. Jyoti Agarwal Dr. Jyoti Bh...
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
 
Ovulation induction
Ovulation inductionOvulation induction
Ovulation induction
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
 

Similar to Oocyte number, female and male age, and ART outcomes

MATCHING OVARIAN RESERVE, OVARIAN RESPONSE AND EMBRYO IMPLANTATION – FROM THE...
MATCHING OVARIAN RESERVE, OVARIAN RESPONSE AND EMBRYO IMPLANTATION – FROM THE...MATCHING OVARIAN RESERVE, OVARIAN RESPONSE AND EMBRYO IMPLANTATION – FROM THE...
MATCHING OVARIAN RESERVE, OVARIAN RESPONSE AND EMBRYO IMPLANTATION – FROM THE...
Sandro Esteves
 
Understanding Strategies to Maximize Cumulative Live Birth Rate
Understanding Strategies to Maximize Cumulative Live Birth RateUnderstanding Strategies to Maximize Cumulative Live Birth Rate
Understanding Strategies to Maximize Cumulative Live Birth Rate
Sandro Esteves
 
Maximizing Outcomes in Assisted Reproductive Technology by Individualization
Maximizing Outcomes in Assisted Reproductive Technology by IndividualizationMaximizing Outcomes in Assisted Reproductive Technology by Individualization
Maximizing Outcomes in Assisted Reproductive Technology by Individualization
Sandro Esteves
 
On invividualization of ovarian stimulation: the arguments in favor
On invividualization of ovarian stimulation: the arguments in favorOn invividualization of ovarian stimulation: the arguments in favor
On invividualization of ovarian stimulation: the arguments in favor
Sandro Esteves
 
Clinical Utility of Sperm DNA Fragmentation Testing: is the jury still out?
Clinical Utility of Sperm DNA Fragmentation Testing: is the jury still out?Clinical Utility of Sperm DNA Fragmentation Testing: is the jury still out?
Clinical Utility of Sperm DNA Fragmentation Testing: is the jury still out?
Sandro Esteves
 
Journal Club - Assisted Reproductive Technology Outcomes in Female-to-Male Tr...
Journal Club - Assisted Reproductive Technology Outcomes in Female-to-Male Tr...Journal Club - Assisted Reproductive Technology Outcomes in Female-to-Male Tr...
Journal Club - Assisted Reproductive Technology Outcomes in Female-to-Male Tr...
Vharshini Manoharan
 
Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?Sandro Esteves
 
Infertility2
Infertility2Infertility2
Infertility2Shambhu N
 
Top Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve ThemTop Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve ThemSandro Esteves
 
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
SSR Institute of International Journal of Life Sciences
 
Estevesevolutionofovarianstimulationforart towardsanindividualizedapproach-fi...
Estevesevolutionofovarianstimulationforart towardsanindividualizedapproach-fi...Estevesevolutionofovarianstimulationforart towardsanindividualizedapproach-fi...
Estevesevolutionofovarianstimulationforart towardsanindividualizedapproach-fi...鋒博 蔡
 
I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad
TECNALIA Research & Innovation
 
Male Infertility for a Generalist
Male Infertility for a GeneralistMale Infertility for a Generalist
Male Infertility for a GeneralistSandro Esteves
 
Ovarian Biomarkers in OI
Ovarian Biomarkers in OIOvarian Biomarkers in OI
Ovarian Biomarkers in OISandro Esteves
 
The Truth About Ovarian Hyperestimulation Syndrome and How to Avoid It
The Truth About Ovarian Hyperestimulation Syndrome and How to Avoid ItThe Truth About Ovarian Hyperestimulation Syndrome and How to Avoid It
The Truth About Ovarian Hyperestimulation Syndrome and How to Avoid ItSandro Esteves
 
Gonadotropins: an evolution perspective
Gonadotropins: an evolution perspectiveGonadotropins: an evolution perspective
Gonadotropins: an evolution perspective
Sandro Esteves
 
Overview of IUGR FGR
Overview of IUGR FGROverview of IUGR FGR
Overview of IUGR FGR
Dr.Laxmi Agrawal Shrikhande
 
Management of Male Infertility
Management of Male InfertilityManagement of Male Infertility
Management of Male InfertilitySandro Esteves
 
Principles and Practices of Individualized OI and IUI
Principles and Practices of Individualized OI and IUIPrinciples and Practices of Individualized OI and IUI
Principles and Practices of Individualized OI and IUI
Sandro Esteves
 
Clinical management of men with nonobstructive azoospermia - Role of IVF Labo...
Clinical management of men with nonobstructive azoospermia - Role of IVF Labo...Clinical management of men with nonobstructive azoospermia - Role of IVF Labo...
Clinical management of men with nonobstructive azoospermia - Role of IVF Labo...
Sandro Esteves
 

Similar to Oocyte number, female and male age, and ART outcomes (20)

MATCHING OVARIAN RESERVE, OVARIAN RESPONSE AND EMBRYO IMPLANTATION – FROM THE...
MATCHING OVARIAN RESERVE, OVARIAN RESPONSE AND EMBRYO IMPLANTATION – FROM THE...MATCHING OVARIAN RESERVE, OVARIAN RESPONSE AND EMBRYO IMPLANTATION – FROM THE...
MATCHING OVARIAN RESERVE, OVARIAN RESPONSE AND EMBRYO IMPLANTATION – FROM THE...
 
Understanding Strategies to Maximize Cumulative Live Birth Rate
Understanding Strategies to Maximize Cumulative Live Birth RateUnderstanding Strategies to Maximize Cumulative Live Birth Rate
Understanding Strategies to Maximize Cumulative Live Birth Rate
 
Maximizing Outcomes in Assisted Reproductive Technology by Individualization
Maximizing Outcomes in Assisted Reproductive Technology by IndividualizationMaximizing Outcomes in Assisted Reproductive Technology by Individualization
Maximizing Outcomes in Assisted Reproductive Technology by Individualization
 
On invividualization of ovarian stimulation: the arguments in favor
On invividualization of ovarian stimulation: the arguments in favorOn invividualization of ovarian stimulation: the arguments in favor
On invividualization of ovarian stimulation: the arguments in favor
 
Clinical Utility of Sperm DNA Fragmentation Testing: is the jury still out?
Clinical Utility of Sperm DNA Fragmentation Testing: is the jury still out?Clinical Utility of Sperm DNA Fragmentation Testing: is the jury still out?
Clinical Utility of Sperm DNA Fragmentation Testing: is the jury still out?
 
Journal Club - Assisted Reproductive Technology Outcomes in Female-to-Male Tr...
Journal Club - Assisted Reproductive Technology Outcomes in Female-to-Male Tr...Journal Club - Assisted Reproductive Technology Outcomes in Female-to-Male Tr...
Journal Club - Assisted Reproductive Technology Outcomes in Female-to-Male Tr...
 
Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?
 
Infertility2
Infertility2Infertility2
Infertility2
 
Top Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve ThemTop Five Problems You Have with Ovulation Induction and How to Solve Them
Top Five Problems You Have with Ovulation Induction and How to Solve Them
 
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
Spectrum of Cervical Lesions by Papanicolaou (Pap) Smear Screening in Remote ...
 
Estevesevolutionofovarianstimulationforart towardsanindividualizedapproach-fi...
Estevesevolutionofovarianstimulationforart towardsanindividualizedapproach-fi...Estevesevolutionofovarianstimulationforart towardsanindividualizedapproach-fi...
Estevesevolutionofovarianstimulationforart towardsanindividualizedapproach-fi...
 
I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad I Jornada Actualización en Genética Reproductiva y Fertilidad
I Jornada Actualización en Genética Reproductiva y Fertilidad
 
Male Infertility for a Generalist
Male Infertility for a GeneralistMale Infertility for a Generalist
Male Infertility for a Generalist
 
Ovarian Biomarkers in OI
Ovarian Biomarkers in OIOvarian Biomarkers in OI
Ovarian Biomarkers in OI
 
The Truth About Ovarian Hyperestimulation Syndrome and How to Avoid It
The Truth About Ovarian Hyperestimulation Syndrome and How to Avoid ItThe Truth About Ovarian Hyperestimulation Syndrome and How to Avoid It
The Truth About Ovarian Hyperestimulation Syndrome and How to Avoid It
 
Gonadotropins: an evolution perspective
Gonadotropins: an evolution perspectiveGonadotropins: an evolution perspective
Gonadotropins: an evolution perspective
 
Overview of IUGR FGR
Overview of IUGR FGROverview of IUGR FGR
Overview of IUGR FGR
 
Management of Male Infertility
Management of Male InfertilityManagement of Male Infertility
Management of Male Infertility
 
Principles and Practices of Individualized OI and IUI
Principles and Practices of Individualized OI and IUIPrinciples and Practices of Individualized OI and IUI
Principles and Practices of Individualized OI and IUI
 
Clinical management of men with nonobstructive azoospermia - Role of IVF Labo...
Clinical management of men with nonobstructive azoospermia - Role of IVF Labo...Clinical management of men with nonobstructive azoospermia - Role of IVF Labo...
Clinical management of men with nonobstructive azoospermia - Role of IVF Labo...
 

More from Sandro Esteves

MODERN REQUIREMENTS OF AN ASSISTED REPRODUCTIVE CENTER OF EXCELLENCE
MODERN REQUIREMENTS OF AN ASSISTED REPRODUCTIVE CENTER OF EXCELLENCEMODERN REQUIREMENTS OF AN ASSISTED REPRODUCTIVE CENTER OF EXCELLENCE
MODERN REQUIREMENTS OF AN ASSISTED REPRODUCTIVE CENTER OF EXCELLENCE
Sandro Esteves
 
Impact of Sperm DNA Fragmentation and Dyszoospermia on Recurrent Implantation...
Impact of Sperm DNA Fragmentation and Dyszoospermia on Recurrent Implantation...Impact of Sperm DNA Fragmentation and Dyszoospermia on Recurrent Implantation...
Impact of Sperm DNA Fragmentation and Dyszoospermia on Recurrent Implantation...
Sandro Esteves
 
Management of Infertile Men with Non-obstructive Azoospermia: clinical and IV...
Management of Infertile Men with Non-obstructive Azoospermia:clinical and IV...Management of Infertile Men with Non-obstructive Azoospermia:clinical and IV...
Management of Infertile Men with Non-obstructive Azoospermia: clinical and IV...
Sandro Esteves
 
Fragmentação do DNA Espermático - Que Aplicações Clínicas?
Fragmentação do DNA Espermático - Que Aplicações Clínicas?Fragmentação do DNA Espermático - Que Aplicações Clínicas?
Fragmentação do DNA Espermático - Que Aplicações Clínicas?
Sandro Esteves
 
Luteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ARTLuteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ART
Sandro Esteves
 
Role of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian StimulationRole of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian Stimulation
Sandro Esteves
 
Air quality: is it that important? And if so, how to measure and control it?
Air quality: is it that important? And if so, how to measure and control it?Air quality: is it that important? And if so, how to measure and control it?
Air quality: is it that important? And if so, how to measure and control it?
Sandro Esteves
 
Técnicas de Obtencão de Espermatozóides na Azoospermia - Como fazer?
Técnicas de Obtencão de Espermatozóides na Azoospermia - Como fazer?Técnicas de Obtencão de Espermatozóides na Azoospermia - Como fazer?
Técnicas de Obtencão de Espermatozóides na Azoospermia - Como fazer?
Sandro Esteves
 
Varicocele e Infertilidade
Varicocele e InfertilidadeVaricocele e Infertilidade
Varicocele e Infertilidade
Sandro Esteves
 
Como Revisar um Artigo Científico
Como Revisar um Artigo CientíficoComo Revisar um Artigo Científico
Como Revisar um Artigo Científico
Sandro Esteves
 
Poder Amostral e Estatística
Poder Amostral e EstatísticaPoder Amostral e Estatística
Poder Amostral e Estatística
Sandro Esteves
 
Novel concepts in male factor infertility: clinical and laboratory perspectives
Novel concepts in male factor infertility: clinical and laboratory perspectivesNovel concepts in male factor infertility: clinical and laboratory perspectives
Novel concepts in male factor infertility: clinical and laboratory perspectives
Sandro Esteves
 
Public lecture - Stem Cell and Male Infertility
Public lecture - Stem Cell and Male InfertilityPublic lecture - Stem Cell and Male Infertility
Public lecture - Stem Cell and Male Infertility
Sandro Esteves
 
Clinical management of men with nonobstructive azoospermia - Sperm Retrieval ...
Clinical management of men with nonobstructive azoospermia - Sperm Retrieval ...Clinical management of men with nonobstructive azoospermia - Sperm Retrieval ...
Clinical management of men with nonobstructive azoospermia - Sperm Retrieval ...
Sandro Esteves
 
Clinical management of men with nonobstructive azoospermia - Steps Before Spe...
Clinical management of men with nonobstructive azoospermia - Steps Before Spe...Clinical management of men with nonobstructive azoospermia - Steps Before Spe...
Clinical management of men with nonobstructive azoospermia - Steps Before Spe...
Sandro Esteves
 
Clinical management of men with nonobstructive azoospermia - Chances of Harve...
Clinical management of men with nonobstructive azoospermia - Chances of Harve...Clinical management of men with nonobstructive azoospermia - Chances of Harve...
Clinical management of men with nonobstructive azoospermia - Chances of Harve...
Sandro Esteves
 
Clinical management of men with nonobstructive azoospermia - Azoospermia Diff...
Clinical management of men with nonobstructive azoospermia - Azoospermia Diff...Clinical management of men with nonobstructive azoospermia - Azoospermia Diff...
Clinical management of men with nonobstructive azoospermia - Azoospermia Diff...
Sandro Esteves
 
Clinical Utility of Sperm DNA Fragmentation Testing in Male Infertility Treat...
Clinical Utility of Sperm DNA Fragmentation Testing in Male Infertility Treat...Clinical Utility of Sperm DNA Fragmentation Testing in Male Infertility Treat...
Clinical Utility of Sperm DNA Fragmentation Testing in Male Infertility Treat...
Sandro Esteves
 
Como preparar sua publicação para ser aceita em uma boa revista?
Como preparar sua publicação para ser aceita em uma boa revista?Como preparar sua publicação para ser aceita em uma boa revista?
Como preparar sua publicação para ser aceita em uma boa revista?
Sandro Esteves
 
Videos Comentados em Infertilidade Masculina
Videos Comentados em Infertilidade MasculinaVideos Comentados em Infertilidade Masculina
Videos Comentados em Infertilidade Masculina
Sandro Esteves
 

More from Sandro Esteves (20)

MODERN REQUIREMENTS OF AN ASSISTED REPRODUCTIVE CENTER OF EXCELLENCE
MODERN REQUIREMENTS OF AN ASSISTED REPRODUCTIVE CENTER OF EXCELLENCEMODERN REQUIREMENTS OF AN ASSISTED REPRODUCTIVE CENTER OF EXCELLENCE
MODERN REQUIREMENTS OF AN ASSISTED REPRODUCTIVE CENTER OF EXCELLENCE
 
Impact of Sperm DNA Fragmentation and Dyszoospermia on Recurrent Implantation...
Impact of Sperm DNA Fragmentation and Dyszoospermia on Recurrent Implantation...Impact of Sperm DNA Fragmentation and Dyszoospermia on Recurrent Implantation...
Impact of Sperm DNA Fragmentation and Dyszoospermia on Recurrent Implantation...
 
Management of Infertile Men with Non-obstructive Azoospermia: clinical and IV...
Management of Infertile Men with Non-obstructive Azoospermia:clinical and IV...Management of Infertile Men with Non-obstructive Azoospermia:clinical and IV...
Management of Infertile Men with Non-obstructive Azoospermia: clinical and IV...
 
Fragmentação do DNA Espermático - Que Aplicações Clínicas?
Fragmentação do DNA Espermático - Que Aplicações Clínicas?Fragmentação do DNA Espermático - Que Aplicações Clínicas?
Fragmentação do DNA Espermático - Que Aplicações Clínicas?
 
Luteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ARTLuteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ART
 
Role of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian StimulationRole of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian Stimulation
 
Air quality: is it that important? And if so, how to measure and control it?
Air quality: is it that important? And if so, how to measure and control it?Air quality: is it that important? And if so, how to measure and control it?
Air quality: is it that important? And if so, how to measure and control it?
 
Técnicas de Obtencão de Espermatozóides na Azoospermia - Como fazer?
Técnicas de Obtencão de Espermatozóides na Azoospermia - Como fazer?Técnicas de Obtencão de Espermatozóides na Azoospermia - Como fazer?
Técnicas de Obtencão de Espermatozóides na Azoospermia - Como fazer?
 
Varicocele e Infertilidade
Varicocele e InfertilidadeVaricocele e Infertilidade
Varicocele e Infertilidade
 
Como Revisar um Artigo Científico
Como Revisar um Artigo CientíficoComo Revisar um Artigo Científico
Como Revisar um Artigo Científico
 
Poder Amostral e Estatística
Poder Amostral e EstatísticaPoder Amostral e Estatística
Poder Amostral e Estatística
 
Novel concepts in male factor infertility: clinical and laboratory perspectives
Novel concepts in male factor infertility: clinical and laboratory perspectivesNovel concepts in male factor infertility: clinical and laboratory perspectives
Novel concepts in male factor infertility: clinical and laboratory perspectives
 
Public lecture - Stem Cell and Male Infertility
Public lecture - Stem Cell and Male InfertilityPublic lecture - Stem Cell and Male Infertility
Public lecture - Stem Cell and Male Infertility
 
Clinical management of men with nonobstructive azoospermia - Sperm Retrieval ...
Clinical management of men with nonobstructive azoospermia - Sperm Retrieval ...Clinical management of men with nonobstructive azoospermia - Sperm Retrieval ...
Clinical management of men with nonobstructive azoospermia - Sperm Retrieval ...
 
Clinical management of men with nonobstructive azoospermia - Steps Before Spe...
Clinical management of men with nonobstructive azoospermia - Steps Before Spe...Clinical management of men with nonobstructive azoospermia - Steps Before Spe...
Clinical management of men with nonobstructive azoospermia - Steps Before Spe...
 
Clinical management of men with nonobstructive azoospermia - Chances of Harve...
Clinical management of men with nonobstructive azoospermia - Chances of Harve...Clinical management of men with nonobstructive azoospermia - Chances of Harve...
Clinical management of men with nonobstructive azoospermia - Chances of Harve...
 
Clinical management of men with nonobstructive azoospermia - Azoospermia Diff...
Clinical management of men with nonobstructive azoospermia - Azoospermia Diff...Clinical management of men with nonobstructive azoospermia - Azoospermia Diff...
Clinical management of men with nonobstructive azoospermia - Azoospermia Diff...
 
Clinical Utility of Sperm DNA Fragmentation Testing in Male Infertility Treat...
Clinical Utility of Sperm DNA Fragmentation Testing in Male Infertility Treat...Clinical Utility of Sperm DNA Fragmentation Testing in Male Infertility Treat...
Clinical Utility of Sperm DNA Fragmentation Testing in Male Infertility Treat...
 
Como preparar sua publicação para ser aceita em uma boa revista?
Como preparar sua publicação para ser aceita em uma boa revista?Como preparar sua publicação para ser aceita em uma boa revista?
Como preparar sua publicação para ser aceita em uma boa revista?
 
Videos Comentados em Infertilidade Masculina
Videos Comentados em Infertilidade MasculinaVideos Comentados em Infertilidade Masculina
Videos Comentados em Infertilidade Masculina
 

Recently uploaded

Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
Levi Shapiro
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
DR SETH JOTHAM
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
touseefaziz1
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Oleg Kshivets
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
DR SETH JOTHAM
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 

Recently uploaded (20)

Prix Galien International 2024 Forum Program
Prix Galien International 2024 Forum ProgramPrix Galien International 2024 Forum Program
Prix Galien International 2024 Forum Program
 
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIONDACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
ACUTE SCROTUM.....pdf. ACUTE SCROTAL CONDITIOND
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
POST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its managementPOST OPERATIVE OLIGURIA and its management
POST OPERATIVE OLIGURIA and its management
 
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdfBENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
BENIGN PROSTATIC HYPERPLASIA.BPH. BPHpdf
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 

Oocyte number, female and male age, and ART outcomes

  • 1. Sandro C. Esteves ANDROFERT & University of Campinas (UNICAMP), Campinas, BRAZIL Aarhus University, DENMARK Oocyte number and success in ART – The “ART Calculator”
  • 2. Esteves, 2 Sandro Esteves, MD., PhD. • Medical and Scientific Director, ANDROFERT, Campinas, BRAZIL • Collaborating Professor, Department of Surgery, University of Campinas (UNICAMP), BRAZIL • Research Collaborator, American Center for Reproductive Medicine, Cleveland Clinic, USA • Research Collaborator, Genetic Unit, Universidad Autónoma de Madrid, SPAIN • Honorary Professor of Reproductive Endocrinology, Faculty of Health, Aarhus University, DENMARK Declare receipt of honoraria for lectures from Merck, Besins, Gedeon Richter, and Lilly Affiliation & Disclosure
  • 3. 1. Importance of oocyte number and female age in ART success 2. Estimation of individualized oocyte number for modelling patient-oriented strategies as a means to increase ART efficiency Lecture Outline Esteves, 3
  • 4. Modified from Smith et al. JAMA 2015 156,947 UK women (257,398 IVF cycles; cumulative LBR using fresh and frozen ET) With increased women’s age in ART programs, we should maximize reproductive outcomes and shorten TTLB Esteves, 4
  • 5. Quality Dimensions 1. Effectiveness (Technical aspects to deliver the best outcome) 2. Safety (risks, adverse effects, lab quality, etc.) 3. Patient centeredness (patient values and preferences) Success in ART The bottom line • Evaluate properly • Give a fair estimate of outcome • Develop a time-limited treatment plan Dancet et al. Hum Reprod 2011; Mainz. Int J Qual Health Care 2003 Esteves, 5
  • 6. AMH and AFC predict ovarian response but not LBR AMH~AFC>FSH>Age Predictors of Poor Response Predictors of Excessive Response Accuracy for Non-Pregnancy Prediction ~ 50-55% Modified from Broer et al. Fertil Steril 2009 Modified from Broer et al. Fertil Steril 2009Modified from Broer et al. Hum Reprod Update 2011 Accuracy ~0.82 Accuracy ~0.78 Esteves, 6
  • 7. Female age and number of oocytes can predict LBR Modified from McLernon et al. BMJ 2016 Modified from Sunkara et al. Hum Reprod 2011 Modified from De Geyter et al. Swiss Med Wkly 2015 Esteves, 7
  • 8. Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number POSEIDON GROUP Poseidon Group. Fertil Steril 2016 Esteves, 8
  • 9. Low prognosis groups Young Older Adequate ovarian reserve Poor ovarian reserve Courtesy of Chloe Xilinas, EXCEMED Poseidon Group. Fertil Steril 2016; Humaidan et al. F1000Research 2016 2 2 Esteves, 9
  • 10. Prevalence of low prognosis patients according to POSEIDON criteria 5% 30% 10% 55% 47% Poseidon 1-4 53% Non Poseidon N=432 – YEAR 2017 Source: ANDROFERT Esteves, 10
  • 11. Modified from Drakopoulos et al. Hum Reprod 2016 Low Prognosis Owing to Decreased Number of Oocytes and thus lower CLBR Poseidon Patients Age-adjusted CLBR strongly influenced by oocyte number * Age adjusted (OR: 0.9; 95% Cl: 0.9-1.01) 21.7% 39.7% 50.5% 61.5%p=0.002 p=0.02 p=0.01 Esteves, 11
  • 12. Group 1 Young & Suboptimal/Low Oocyte Number Group 2 Old & Suboptimal/Low Oocyte Number Group 3 Young & Expected Low Oocyte Number Group 4 Old & Expected Low Oocyte Number High embryo aneuploidy risk Low embryo aneuploidy risk Few embryos generated Reduced Cumulative Live Birth Rate Poseidon Patients Esteves, 12
  • 13. Esteves et al., ESHRE 2018; P-394 The older the women the lower the probability of euploid embryos, thus increasing the risk of NO transferable embryos Euploidy probability vs Female age Cycles with no transferable embryos Courtesy of Chloe Xilinas, EXCEMED Courtesy of Ubaldi & Rienzi. Genera Jan 2012 – Dec 2013 Esteves, 13
  • 14. Estimation of Age-dependent Decrease in Blastocyst Euploidy by Next Generation Sequencing - Development of a Novel Prediction Model Quadratic model on age significant (Prob>ChiSquare=0.028); derived model was log[p(t)/(1−p(t))]=7.575-0.21⋅age-0.011⋅(age-38.41)2, where p(t) is the probability of a blastocyst being euploid for age (t) in years. Term Estimate Std Error Wald ChiSquare Prob > ChiSquare Lower 95% Upper 95% Intercept 7.5746663 1.028021 54.290324 <.0001* 5.5597808 9.5895518 age -0.212288 0.026273 65.284544 <.0001* -0.263783 -0.160793 (age- 38.4082)*(age- 38.4082) -0.01059 0.004834 4.7979866 0.0285* -0.020066 -0.001114 Esteves, Carvalho, Martinhago, Melo, Bento, Humaidan & Alviggi. Panminerva Medica 2018 ahead of print Esteves, 14
  • 15. Euploidy probability vs Female age Measure Training Validation Number of rows 1,036 260 Sum of Frequencies 1,036 260 -LogLikelihood 588.50165 139.70103 Number of Parameters 3 3 BIC 1197.6537 295.89356 AICc 1183.028 285.50206 Generalized RSquare 0.1162863 0.1893375 Validation by randomly splitting 80% of the data for training and 20% for testing Esteves, Carvalho, Martinhago, Melo, Bento, Humaidan & Alviggi. Panminerva Medica 2018 ahead of print Esteves, 15
  • 16. Esteves et al., ESHRE 2018; O-007 Progressive decline* in blastocyst euploidy probability as a function of female age Analysis of 1,220 trophectoderm biopsies from 436 patients undergoing ICSI and PGT-A with NGS 1.2 1.9 2.6 3.4 4.4 5.5 6.7 8.2 9.8 11.6 13.6 15.7 17.9 20.2 22.4 24.5 26.6 Geometric mean of the yearly variation: 13.6% *The % decrease in blastocyst euploidy probability from year (t) to year (t+1) was defined as the ratio p(t+1)/p(t) x 100 Esteves, 16
  • 17. Number of oocytes needed to maximize live births should be individualized Female age is a critical factor to be taken into account Patient-oriented strategies can be used to achieve the individualized oocyte number Esteves, 17
  • 18. Introduced an Intermediate Marker of Success in ART: the Ability to Retrieve the Number of Oocytes Needed to Obtain at Least One Euploid Blastocyst for Transfer in Each Patient Poseidon Group. Fertil Steril 2016; Humaidan et al. F1000Research 2016 What is new in POSEIDON? Introduced the Concept of ‘Low Prognosis’ in ART Combined Oocyte Quality and Quantity for Identification and Stratification of the ’Low Prognosis’ Patient Included ’Hypo-responders’ as a Distinct Category of ’Low Prognosis’ Patients Introduced an Intermediate Marker of Success in ART: the Ability to Retrieve the Number of Oocytes Needed to Obtain at Least One Euploid Blastocyst for Transfer in Each Patient Esteves, 18
  • 19. Courtesy of Ubaldi & Rienzi (GENERA; Jan 2012-Dez 2013) Source: ANDROFERT; Jan 2015-Sept 2016 (PGT-A by NGS) Live birth (%) Availability of euploid embryos maximizes IVF efficiency by offsetting the negative effect of age on implantation and pregnancy Esteves, 19
  • 20. http://www.members.groupposeidon.com/Calculator Estimation can be done by means of a mathematical function taking into account relevant predictive factors Input variables • Maturation rate • 2PN Fertilization rate • Cleavage or Blastulation rate • Euploidy rate per age group Adjusted according to maternal and paternal age, sperm source, sperm and oocyte status, and type of embryo transfer (fresh; FET) Output variable Y (N oocytes) Function Y = f(X) Esteves, 20
  • 21. There are two ways to do that… the HARD WAY the EASY WAYand Esteves, 21
  • 23. age p N (P=0.8) N (P=0.9) 28 0.6748 2 3 29 0.6665 2 3 30 0.6538 2 3 31 0.6365 2 3 32 0.6144 2 3 33 0.5873 2 3 34 0.5549 2 3 35 0.5174 3 4 36 0.4750 3 4 37 0.4283 3 5 38 0.3784 4 5 39 0.3268 5 6 40 0.2753 5 8 41 0.2259 7 9 42 0.1803 9 12 43 0.1399 11 16 44 0.1056 15 21 45 0.0775 20 29 Minimum number (N) of blastocysts required to achieve at least one euploid blastocyst for transfer, with probabilities (P) of 0.8 and 0.9, where “p” is the model-estimated probability of a blastocyst being euploid for female age in years Esteves, Carvalho, Martinhago, Melo, Bento, Humaidan & Alviggi. Panminerva Medica 2018 ahead of print Esteves, 23
  • 24. Model Estimates (No. embryos by female age) Esteves, Carvalho, Martinhago, Melo, Bento, Humaidan & Alviggi. Panminerva Medica 2018 ahead of print Esteves, 24
  • 26. The most optimal treatment strategy is planned with the mindset to achieve the POSEIDON marker of success GnRH analogue regimen Gonadotropin dose and drug type Trigger strategy Adjuvant therapy Combined strategies (AccuVit; Duostim, etc.) Personalized use of laboratory technology Personalized luteal phase support Esteves, 26
  • 27. Agonist or Antagonist + rFSH alone or rFSH + LH Agonist or Antagonist + rFSH + LH GnRH Antagonist + Low dose rFSH (100-175 IU) GnRH Antagonist + rFSH + LH Poseidon G1 Poseidon G2 Poseidon G3 Poseidon G4 Non Poseidon patients Andersen et al. (eds.) Research Topic Frontiers in Endocrinology. In preparation It is important to use the right FSH starting dose and adapt it during the cycles to optimize the number of oocytes retrieved and at the same time minimize risks such as OHSS and cycle cancellation Esteves, 27
  • 28. Esteves, Yarali, Ubaildi et al. Validation of ART Calculator Consortium; Unpublished data No detrimental effects on embryo ploidy in patients who retrieve more oocytes Response Number Euploid Blastocysts Distribution Binomial Estimation Method Logistic Regression Validation Method Validation Column Probability Model Link Logit Generalized Regression for number Euploid Blastocysts Model Launch Lasso [x] Adaptive Term Estimate Std Error Wald ChiSquare Prob > ChiSquare Lower 95% Upper 95% Intercept 6.2769104 0.6256681 100.64771 <0.0001* 5.0506235 7.5031972 Age Female -0.182507 0.152275 143.64894 <0.0001* -0.212352 -0.152662 Number Blastocysts 0.0302516 0.0189943 2.536584 0.1112 -0.006977 0.0674797 Parameter Estimates for Original Predictors 3,108 Trophectoderm Biopsies 1,109 patients Euploidy probability vs. number of blastocysts by age group Esteves, 28
  • 29. Higher ovarian response than that achieved with mild/natural ovarian stimulation does not increase risk of embryo aneuploidy Term Estimate Std Error Wald ChiSquare Prob > ChiSquare Lower 95% Upper 95% Intercept 3.8117137 1.5331832 6.1809102 0.0129* 0.8067298 6.8166876 Age Female -0.22129 0.019748 125.56789 <0.001* -0.259996 -0.182585 typeOSGrou ped[Convent ional-Other] 0.065727 0.33909 0.0375714 0.8463 -0.598877 0.7303311 Response Number Euploid Blastocysts Distribution Binomial Estimation Method Adaptive Lasso Validation Method Validation Column Probability Model Link Logit Adaptive Lasso with Validation Column Model Summary Parameter Estimates for Original Predictors 1,632 Trophectoderm Biopsies by NGS 631 patients Euploidy probability vs Female Age, by OS Type Esteves, Yarali, Ubaildi, et al. Validation of ART Calculator Consortium; Unpublished data Esteves, 29
  • 30. Administration of an inappropriately low gonadotrophin dose may lead to the growth of a low number of follicles resulting in an ‘iatrogenic’ poor or suboptimal response • Type of Gonadotropin • FSH Dose • Add LH Courtesy of Chloe Xilinas, EXCEMED Esteves, 30
  • 31. Unpublished data; Source: ANDROFERT Current Practice – Flexibility of iCOS Rec-hFSH Starting Dose Distribution (%) % cycles with Dose Adaptation after Sd5 53.4% Esteves, 31
  • 32. Current Practice – Flexibility of iCOS % cycles by Trigger Method % cycles with LH Activity Supplementation 12% Dual trigger 43% GnRH analog 45% hCG 57% Rec-LHc 43% No-LH Unpublished data; Source: ANDROFERT Esteves, 32
  • 33. Target number of oocytes difficult to achieve by a single OS cycle http://www.members.groupposeidon.com/Calculator Courtesy of Chloe Xilimas, EXCEMED Esteves, 33
  • 34. Haahr, Esteves & Humaidan. Reprod Biol Endocrinol 2018 Management of Poseidon poor prognosis patients <AFC <5 and/or AMH <1.2 ng/ml Group 3, young (AGE <35) Group 4, old (AGE ³35) Poor reserve - good quality Poor reserve - poor quality Reason for poor response: • Poor ovarian reserve • Asynchronous development (Genetic polymorphism of FSH-R; LH-R; V-LH-β) iCOS Treatment: • Long GnRHa protocol • GnRH antagonist (E2, OCP) • DuoStim ? • Stimulation with 300 IU/d rFSH • Androgens ? Embryo Transfer strategy: • Fresh transfer • Oocyte/embryo accumulation and FET Measure of success: In average, a total of 4-5 oocytes are needed to obtain one euploid embryo Reason for poor response: • Poor ovarian reserve • Asynchronous development • High Aneuploidy rate (Genetic polymorphism of FSH-R; LH-R; V-LH-β) iCOS Treatment: • Long GnRHa protocol • GnRH antagonist (E2, OCP) • DuoStim • Stimulation with 300 IU/d rFSH • Androgens ? Embryo Transfer strategy: • Fresh transfer • Oocyte/embryo accumulation, PGS? and FET (Oocyte donation) Measure of success: In average, a total of 12 oocytes are needed to obtain one euploid embryo Esteves, 34
  • 35. Modified from Ubaldi et al. Fertil Steril 2016 Dual stimulation Courtesy of Chloe Xilinas, EXCEMED rFSH or rFSH+LH rFSH or rFSH+LH Esteves, 35
  • 36. Male age! Does it matter?
  • 37. Ramajit Raghav, 94 yo. Indian farmer claims to be the oldest dad in the world, and says he wants more…
  • 39. Review Criteria An extensive search of studies examining the influence of paternal age on ART outcomes was performed using PubMed and MEDLINE. The start date for the search was January 2008, and the end date was March 2018. The overall strategy for study identification and data extraction was based on the following keywords: “paternal age”, “male age factor”, “masculine age factor”, “male ageing”, “paternal ageing”, “reproductive techniques”, “assisted”, “ICSI”, “in vitro fertilization” “sperm injections”, “intracytoplasmic”, “IVF”, with the filters “humans” and “English language.” Data that were solely published in conference or meeting proceedings, websites or books were not included. Citations dated outside the search dates were only included if provided conceptual content. ESTEVES, 39CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 39
  • 40. Study Country Number Main findings Age cutoff Frattarelli 2008 USA 1023 Decline in semen volume and total motile sperm number 45 Bellver 2008 Spain 2698 Negative association between age and semen volume, sperm concentration, and total progressive motility NR Girsh, 2008 Israel 484 Male age higher in non-pregnant group; Conventional semen parameters lower in men aged >50 50 Ferreira, 2010 Brazil 1024 No effect of age on sperm concentration and motility NR Duran 2010 USA 408 Semen volume, sperm motility and fertilization rates inversely correlated with age NR Nijs, 2011 Belgium 278 No correlation between male age and sperm concentration, progressive motility, and DFI NR Varshini, 2011 India 504 DFI increased in men older than 40 years 40 Stone, 2013 USA 5081 Total sperm numbers fall by ~2% per year, morphology by ~0.8% per year, and total sperm motility by ~2% 35 Alshahrani, 2014 USA 472 No significant differences in conventional semen parameters. Higher DFI in men >40y 40 Beguería, 2014 Spain 4887 Semen volume and %motile sperm decreased with a mean reduction of 0.22 ml and 1.2% every 5 years NR Kaarouch, 2018 Morocco 204 No effect on conventional semen parameters; Higher DFI and sperm aneuploidy in older men 40 Paternal age X semen parameters Bertoncelli Tanaka et al. Panminerva Med. 2018 Jul 18. [Epub ahead of print]
  • 41. Author Country Number (cycles) Method Egg donation model Fertilization Embryo development Pregnancy Miscarriage/ stillbirth Live birth Age cutoff Gu, 2012 China 103 IVF Yes No effect NR No effect No effect No effect NA Robertshaw, 2014 USA 237 IVF Yes NR NR NR Increase in pregnancy loss with aging 26% lower odds of LB with each 5- year increase in age NR Wu, 2015 China 9991 IVF No No effect No effect Lower in men >36y than <32 y (women 30-34y) No effect No effect 36 Girsh, 2008 Israel 484 ICSI Yes No effect Decreased Decreased NR NR 40-50 Ferreira, 2010 Brazil 1024 ICSI No NR No effect Decreased by 5% for each year of age in oligozoospermia No effect NR NR Tsai, 2013 Taiwan 184 ICSI No No effect No effect No effect No effect No effect NA Ramasamy, 2014 USA 1046 ICSI No NR NR Decreased NR NR 50 Beguería, 2014 Spain 4887 ICSI Yes No effect No effect No effect No effect No effect NA Frattarelli, 2008 USA 1023 IVF and ICSI No No effect Reduced blastocyst formation No effect Increased miscarriage Decreased 55 Bellver, 2008 Spain 2698 IVF and ICSI Yes No effect No effect No effect No effect NR NA Campos, 2008 Spain 915 IVF and ICSI Yes No effect No effect Decreased No effect NR 39 Luna, 2009 USA 672 IVF and ICSI Yes Decreased Reduced blastocyst formation No effect No effect NR 40* and 60‡ Duran, 2010 USA 519 IVF and ICSI Yes Decreased No effect No effect No effect No effect 50 Ghuman, 2016 UK 7104 IVF and ICSI No NR NR No effect No effect NR NA Meijerink, 2016 Netherlands 7051 IVF and ICSI No No effect No effect No effect NR NR NA McPherson, 2017 Australia 2215 IVF and ICSI No No effect NR See LBR NR 10% lower pregnancy and LBR in women aged 35 years with partners >40 years than women aged 35 years with partners <30 years 40 Tiegs, 2017 USA 573 IVF and ICSI Yes Decreased No effect No effect No effect No effect 45 Chapuis, 2017 France 2491 IVF and ICSI No No effect Reduced blastocyst formation Decreased in ICSI but not with IVF No effect — 50 Park, 2017 Korea 452 ICSI No No effect No effect Decreased NR Decreased 46 Kaarouch, 2018 Morocco 83 IVF No Decreased Decreased Decreased Increased NR 40 Bertoncelli Tanaka et al. Panminerva Med. 2018 Jul 18. [Epub ahead of print] Paternal age X IVF outcomes ESTEVES, 41
  • 42. ESTEVES, 42 ESTEVES, 42 CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA
  • 43. ESTEVES, 43 Esteves, Yarali, Ubaldi et al; ART Calculator Validation Consortium, Unpublished data Paternal age and blastocyst genetic status 1070 patients TB + NGS CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 43
  • 44. Age CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 44 Cho, Esteves, Agarwal. Curr Opin Obstet Gynecol 2016 Finding the link
  • 45. Aitken, Reproduction 2014; 147:S1-S11 Mechanism of oxidative-induced sperm DNA damage OGG1: 8-oxi guanine glicosylase CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 45 Activity of OGG1 decreases with advanced paternal age, thus resulting in 8-oxi guanine accumulation
  • 46. Sperm chromatin repair mechanisms CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 46 Champroux et al. Basic and Clin Androl 2016; 26:17 OGG1 is deficient in oocytes; 8OHdG carried to embryos by fertilizing sperm 8OHdG highly mutagenic (G-T transversion)
  • 47. proband schizophrenic Kong et al. Nature 2012; 488:471 proband a parent of an autistic case ♦ proband autistic An exponential model estimates paternal mutations doubling every 16.5 years Paternal age and germline mutations CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 47
  • 48. Guanine particularly vulnerable Oxidative stress causes harm to DNA No.oxidizedregions Chromosome size Imunoprecipitação 8OHdG chrX chrY chr15 CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 48
  • 49. Impact of paternal age on neurodevelopmental status of naturally conceived offspring Autism Bipolar disease/schizophrenia Marfan syndrome Paternal age (yrs) Oddsratio Bipolar disease Frans et al. Arch Gen Psychiatry 2008; 65:1034 Paternal age (yrs) Oddsratio Autism Reichenberg et al. Arch Gen Psychiatry 2006; 63:1026 CLÍNICA DE ANDROLOGIA E LABORATÓRIO DE REPRODUÇÃO HUMANA CENTRO DE REFERÊNCIA PARA REPRODUÇÃO MASCULINA ESTEVES, 49
  • 50. POSEIDON–based Stratification FSH Starting Dose Gonadotropin Dose Adaptation Flexible OS (eg. LH, Duostim, trigger) Maximize oocyte yield to achieve estimated N oocytes for at least 1 euploid embryo (ART Calculator) Reduced Time to Live Birth Conclusions Esteves, 50